FDA Opens De-Regulation Docket To Collect Ideas For Repealing, Modifying Deficient Rules
This article was originally published in The Pink Sheet Daily
Executive Summary
House oversight committee hears plea for more transparent, predictable regulatory processes at FDA.
You may also be interested in...
Bar Code Rule Could Be Revised Under FDA Reg Review Initiative
Technological advances allow the agency to consider alternatives to the requirements in the current rule, which became effective in 2006.
Bar Code Rule Could Be Revised Under FDA Reg Review Initiative
Technological advances allow the agency to consider alternatives to the requirements in the current rule, which became effective in 2006.
PhRMA Seeks Repeal Of Brand Name Review Rule Until A Benefit Is Shown
The pharmaceutical industry wants FDA to prove its proprietary name review program is worth the effort.